Atgc Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 15-11-2024
- Paid Up Capital ₹ 1.20 Cr
as on 15-11-2024
- Company Age 13 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.08 Cr
as on 15-11-2024
- Revenue -53.34%
(FY 2023)
- Profit -49.69%
(FY 2023)
- Ebitda -9.77%
(FY 2023)
- Net Worth 408.64%
(FY 2023)
- Total Assets -3.21%
(FY 2023)
About Atgc Biotech
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.20 Cr.
The company currently has active open charges totaling ₹10.08 Cr.
Markandeya Gorantla and Sivarama Prasad serve as directors at the Company.
- CIN/LLPIN
U24232TG2011PTC075066
- Company No.
075066
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jun 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
- Apps
What products or services does Atgc Biotech Private Limited offer?
Atgc Biotech Private Limited offers a wide range of products and services, including .
Who are the key members and board of directors at Atgc Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Markandeya Gorantla  | Managing Director | 25-Nov-2014 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sivarama Prasad | Director | 20-Jun-2011 | Current |
Financial Performance and Corporate Structure Insights of Atgc Biotech.
Atgc Biotech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 53.34% decrease. The company also saw a substantial fall in profitability, with a 49.69% decrease in profit. The company's net worth Soared by an impressive increase of 408.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Atgc Biotech?
In 2023, Atgc Biotech had a promoter holding of 51.42% and a public holding of 48.58%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Bharath Advanced Therapeutics Private LimitedActive 11 months
Markandeya Gorantla is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 19 Jan 2024 | ₹10.00 Cr | Open |
Hdfc Bank Limited Creation Date: 10 May 2021 | ₹0.76 M | Open |
How Many Employees Work at Atgc Biotech?
Atgc Biotech has a workforce of 52 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Atgc Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Atgc Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
